History
SideROS was founded in January 2019 based on the research from Dr Raphaël Rodriguez, a world renowned scientist devoted to understand persistent cancer cells biology, the role of iron homeostasis in those cells and know how to target them.
The company was first incubated at Institut du Cerveau before joining Paris Biotech Santé incubator in September 2020.
Vision & Mission
SideROS aims to improve the conditions of patients affected by life-threatening diseases lacking of effective treatment.
SideROS promotes the development of innovative research on iron-targeting chemical compounds to target persistent cancer cells, refractory to conventional treatments and associated to metastasis and relapse.
Disturbing tumor cells metabolism, through specific inhibition of iron metabolism, is a novel targeted treatment.
Values
SideROS team, advisors and executives are our source of strength promoting teamwork, respect, and challenges to create and develop innovative small molecules targeting tumor cells metabolism in high-risk cancers with poor prognosis with the aim of improving patients quality of life.
The team
